Sannovex Pharmaceuticals

SANNOVEX Pharmaceuticals’ field force started in 2010 with the arrival of Sannovex branded products from global manufacturers in China, India and later in Europe in 2011. It started with ten (10) medical representatives, increased to twenty five (25) in 2011, forty (40) in 2012, and eighty (80) in the fourth quarter of 2013 under two divisions, Line 1 and Line 2. SANNOVEX Pharmaceuticals markets products in injection forms but has started in 2013 negotiations for licensing & manufacturing agreement for oral preparations & expanding preparations for injections with European manufacturers for its Cardio-metabolic division, Anti-Infectives, Gastro-Intestinal, Oncology, CNS, Anti-Allergy, Analgesic, Anti-inflammatory products & non ethical preparations during the CPhI Frankfurt, Germany convention. The marketing of Sannovex branded products is limited to molecules that are already off patent and those classified as highly essential drugs in the Philippine National Drug Formulary that bridges the gap between efficacy and affordability of high quality medicines. Sannovex target clients are basically private and government major and minor hospitals with good credit standing.